MedTrace Logo

TIP (Paclitaxel + Ifosfamide + Cisplatin) Combined With Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer

NCT04475016 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2022-06-09

No results posted yet for this study

Summary

Primary Objective:To evaluate the efficacy and safety of TIP (paclitaxel + ifosfamide + cisplatin) combined with nimotuzumab \& triprilimab as neoadjuvant treatment in locally advanced penile cancer.

Conditions

  • Penile Cancer

Interventions

DRUG

Albumin-Bound Paclitaxel

260 mg/m² IV over 30 minutes on Day 1

DRUG

Ifosfamide

1200 mg/m² IV over 2 hours on Days 1-3

DRUG

Cisplatin

25 mg/m² IV over 2 hours on Days 1-3

DRUG

Nimotuzumab

400 mg IV on Day 1

DRUG

Triprilimab

240 mg IV on Day 1

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-12
Primary Completion
2022-05-06
Completion
2022-05-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04475016 on ClinicalTrials.gov